Home » Topics » Regulatory » EMA

EMA
RSS

EMA approves Vectibix for metastatic colorectal cancer expressing wild-type RAS

April 7, 2015

EMA committee recommends approval of Akynzeo

April 1, 2015

EMA committee hands down positive opinion for Lenvima in differentiated thyroid carcinoma

March 31, 2015

CHMP recommends approval of empagliflozin/metformin for type 2 diabetes

March 31, 2015

EMA validates Zinbryta MAA for relapsing forms of MS

March 31, 2015

EMA grants orphan drug designation to Reolysin for gynecological cancers

March 25, 2015

EMA grants orphan status to Kamada treatment for graft-versus-host disease

March 25, 2015

Stempeucel receives EMA advanced therapy medicinal product classification

March 24, 2015

NovImmune's HLH trial of NI-0501 allows first-line treatment after protocol amendment

March 19, 2015

ImMucin receives E.U. orphan drug designation for multiple myeloma

March 17, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...